Description
Background:
Pasotuxizumab is a canonical PSMA x CD3 BiTE molecule with potent in vitro and in vivo cytotoxicity activity. It is under investigation as an immune therapy mediating T-cell killer of tumor cells in patients with advanced castration-resistant prostate cancer.
Intended Use:
For Estimation of Pasotuxizumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!